FTC probes Bristol-Myers Squibb over generic Plavix

April 9, 2007

The FTC launched a civil investigation requesting that Bristol-Myers Squibb turn over key documents and information surrounding a reverse-payment deal it and Sanofi-Aventis made with generic firm Apotex to delay market entry of generic clopidogrel bisulfate (Plavix).

The FTC launched a civil investigation requesting that Bristol-Myers Squibb (BMS) turn over key documents and information surrounding a reverse-payment deal it and Sanofi-Aventis made with generic firm Apotex to delay market entry of generic clopidogrel bisulfate (Plavix). BMS said that it would cooperate with FTC officials. The commission served BMS with a Civil Investigation Demand and requested that the company provide the appropriate documents and information relating to the proposed settlement with Apotex of the Plavix patent litigation that is pending in the U.S. District Court. The newest investigation by the FTC comes in the wake of BMS' being cleared in a criminal probe by the antitrust division of the Department of Justice.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.